Economic Burden of Type 1 Diabetes in France
Authors' conclusion
Our results suggest that the most advanced insulin delivery devices have a significant short-term economic impact.
Study context
- Population
- Adults aged ≥18 years with T1D in the SFDT1 cohort, France, insurance claims for 2023matched cohort
- Exposure
- Adults with T1D vs matched patients without diabetes
- Outcome
- Societal costs of T1D (direct and indirect costs)
- Follow-up
- 2023
Methodological detailsdescriptive, retrospective, matched cohort, insurance claim data analysis
- Descriptive
- Retrospective
- Matched cohort
- Insurance claim data analysis
Main finding
As reported in the abstract
Average individual societal cost of T1D vs absence of diabetes
- Average individual societal cost of T1D vs absence of diabetes
- €9940
- Average individual direct costs only
- €9340
- Share of costs attributable to medical devices
- Nearly half
Observational data: associations, not effects.
Further findings
| Outcome | Closed-loop | Pump | MDI |
|---|---|---|---|
| Average costs by treatment modality · 2023 | average €13 557 | average €11 062 | average €7004 |
Total cost of T1D in France (extrapolated), excluding undiagnosed cases and premature mortality · 2023
- Total cost of T1D in France
- between €1.59 and €1.79 billion
Original publication
Economic Burden of Type 1 Diabetes in France. Diabetes Obes Metab. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →